Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Current Liabilities (2020 - 2025)

Barinthus Biotherapeutics' Total Current Liabilities history spans 6 years, with the latest figure at $10.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 36.02% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, down 36.02%, while the annual FY2025 figure was $10.0 million, 36.02% down from the prior year.
  • Total Current Liabilities reached $10.0 million in Q4 2025 per BRNS's latest filing, down from $10.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $18.6 million in Q3 2023 to a low of $6.4 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $12.5 million, with a median of $12.2 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: soared 120.2% in 2022, then tumbled 36.02% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $11.2 million in 2021, then rose by 9.72% to $12.2 million in 2022, then rose by 2.91% to $12.6 million in 2023, then increased by 24.28% to $15.7 million in 2024, then crashed by 36.02% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Total Current Liabilities are $10.0 million (Q4 2025), $10.8 million (Q3 2025), and $12.7 million (Q2 2025).